Therefore, the identification of new drugs that do not depend for their anticancer activity on wild-type p53 status is an important goal since both NSCLC and ovarian cancer patients with p53 mutation have shorter overall survival as well as shorter time to progression [44, 45]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.